Cerebral amyloid angiopathy: Emerging concepts

Journal of Stroke

Volumn 17, Issue 1, 2015, Pages 17-30

  Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Amyloid protein; Cerebral amyloid angiopathy; Cerebrospinal fluid; Cerebrovascular disorders; MRI; PET

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; BETA SECRETASE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA SECRETASE; GELSOLIN; IMMUNOGLOBULIN LIGHT CHAIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHOPROTEIN; PONEZUMAB; PREALBUMIN; PRESENILIN 1; PRION PROTEIN; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

AGING; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ASSESSMENT OF HUMANS; BOSTON CRITERIA; BRAIN BLOOD VESSEL; BRAIN DISEASE; BRAIN INFARCTION; CEREBROSPINAL FLUID LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CORTICAL SUPERFICIAL SIDEROSIS; DEMENTIA; DOPPLER FLOWMETRY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; RISK FACTOR; SIDEROSIS; SUBARACHNOID HEMORRHAGE; VASCULAR AMYLOIDOSIS;

EID: 84935024077     PISSN: 22876391     EISSN: 22876405     Source Type: Journal    
DOI: 10.5853/jos.2015.17.1.17     Document Type: Review

References (124)

1. Scholz W. Studien zur Pathologie der Hirngefäße II. Die drusige Entartung der Hirnarterien und Kapillaren. Z ges Neurol Psychi­at 1938;162:694-715.
2. Surbek B. L’angiopathie dyshorique (Morel) de l’écorce céré­brale. Acta Neuropathol 1961;1:168-197.
3. Pantelakis S. Un type particulier d’angiopathie sénile du sys­tème nerveux central: l’angiopathice congophile. Topographie et fréquence. Mschr Psychiatr Neurol 1954;128:219-256.
4. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311-324.
5. Yamada M, Naiki H. Cerebral amyloid angiopathy. Prog Mol Biol Transl Sci 2012;51:41-78.
6. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M. Cerebral amyloid angiopathy in the aged. J Neurol 1987;234:371-376.
7. Masuda J, Tanaka K, Ueda K, Omae T. Autopsy study of inci­dence and distribution of cerebral amyloid angiopathy in Hi­sayama, Japan. Stroke 1988;19:205-210.
8. Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann N Y Acad Sci 2002;977:37-44.
9. Hirohata M, Yoshita M, Ishida C, Ikeda SI, Tamaoka A, Kuzu­hara S, et al. Clinical features of non-hypertensive lobar intra­cerebral hemorrhage related to cerebral amyloid angiopathy. Eur J Neurol 2010;17:823-829.
10. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer’s disease. An immunoelectron microscopic study. Am J Pathol 1992;141: 249-259.
11. Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredi­ci K, Braak H. Two types of sporadic cerebral amyloid angiop­athy. J Neuropathol Exp Neurol 2002;61:282-293.
12. Mandybur TI. Cerebral amyloid angiopathy: the vascular pa­thology and complications. J Neuropathol Exp Neurol 1986; 45:79-90.
13. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30:637-649.
14. Maeda A, Yamada M, Itoh Y, Otomo E, Hayakawa M, Mi­yatake T. Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy. Stroke 1993;24:1857-1864.
15. Prelli F, Castano E, Glenner GG, Frangione B. Differences be­tween vascular and plaque core amyloid in Alzheimer’s dis­ease. J Neurochem 1988;51:648-651.
16. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble β1-40 is linked to cerebral amy­loid angiopathy. Am J Pathol 1994;145:452-460.
17. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accu­mulates in putative interstitial fluid drainage pathways in Al­zheimer’s disease. Am J Pathol 1998;153:725-733.
18. Yamada M. Predicting cerebral amyloid angiopathy-related in­tracerebral hemorrhages and other cerebrovascular disorders in Alzheimer’s disease. Front Neurol 2012;3:64.
19. Samarasekera N, Smith C, Al-Shahi Salman R. The associa­tion between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2012;83:275-281.
20. Meretoja A, Strbian D, Putaala J, Curtze S, Haapaniemi E, Mustanoja S, et al. SMASH-U: a proposal for etiologic classi­fication of intracerebral hemorrhage. Stroke 2012;43:2592-2597.
21. Yeh SJ, Tang SC, Tsai LK, Jeng JS. Pathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification system. Stroke 2014;45:2636-2642.
22. Béjot Y, Cordonnier C, Durier J, Aboa-Eboulé C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain 2013;136: 658-664.
23. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cere­bral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993;116:135-141.
24. Yamada M, Itoh Y, Otomo E, Hayakawa M, Miyatake T. Sub­arachnoid haemorrhage in the elderly: a necropsy study of the association with cerebral amyloid angiopathy. J Neurol Neuro­surg Psychiatry 1993;56:543-547.
25. Ohshima T, Endo T, Nukui H, Ikeda S, Allsop D, Onaya T. Cerebral amyloid angiopathy as a cause of subarachnoid hem­orrhage. Stroke 1990;21:480-483.
26. Hanyu H, Tanaka Y, Shimizu S, Takasaki M, Abe K. Cerebral microbleeds in Alzheimer’s disease. J Neurol 2003;250:1496-1497.
27. Nakata-Kudo Y, Mizuno T, Yamada K, Shiga K, Yoshikawa K, Mori S, et al. Microbleeds in Alzheimer disease are more relat­ed to cerebral amyloid angiopathy than cerebrovascular dis­ease. Dement Geriatr Cogn Disord 2006;22:8-14.
28. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Bark­hof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66:1356-1360.
29. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007;130: 1988-2003.
30. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 2008;65:790-795.
31. Brundel M, Heringa SM, de Bresser J, Koek HL, Zwanenburg JJ, Jaap Kappelle L, et al. High prevalence of cerebral microbleeds at 7Tesla MRI in patients with early Alzheimer’s disease. J Alzheimers Dis 2012;31:259-263.
32. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010;74:1346-1350.
33. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC, et al. Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease. Neurology 2011; 77:48-54.
34. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010;68: 545-548.
35. Gurol ME, Dierksen G, Betensky R, Gidicsin C, Halpin A, Becker A, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012; 79:320-326.
36. van Etten ES, Auriel E, Haley KE, Ayres AM, Vashkevich A, Schwab KM, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke 2014;45:2280-2285.
37. Feldman HH, Maia LF, Mackenzie IR, Forster BB, Martzke J, Woolfenden A. Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. Stroke 2008;39:2894-2897.
38. Kumar S, Goddeau RP Jr, Selim MH, Thomas A, Schlaug G, Alhazzani A, et al. Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies. Neurology 2010;74:893-899.
39. Vernooij MW, Ikram MA, Hofman A, Krestin GP, Breteler MM, van der Lugt A. Superficial siderosis in the general population. Neurology 2009;73:202-205.
40. Charidimou A, Peeters AP, Jäger R, Fox Z, Vandermeeren Y, Laloux P, et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology 2013;81:1666-1673.
41. Shoamanesh A, Martinez-Ramirez S, Oliveira-Filho J, Reijmer Y, Falcone GJ, Ayres A, et al. Interrelationship of superficial siderosis and microbleeds in cerebral amyloid angiopathy. Neurology 2014;83:1838-1843.
42. Linn J, Wollenweber FA, Lummel N, Bochmann K, Pfefferkorn T, Gschwendtner A, et al. Superficial siderosis is a warning sign for future intracranial hemorrhage. J Neurol 2013; 260:176-181.
43. Wollenweber FA, Buerger K, Mueller C, Ertl-Wagner B, Malik R, Dichgans M, et al. Prevalence of cortical superficial siderosis in patients with cognitive impairment. J Neurol 2014;261: 277-282.
44. Zonneveld HI, Goos JD, Wattjes MP, Prins ND, Scheltens P, van der Flier WM, et al. Prevalence of cortical superficial siderosis in a memory clinic population. Neurology 2014;82:698-704.
45. Izenberg A, Aviv RI, Demaerschalk BM, Dodick DW, Hopyan J, Black SE, et al. Crescendo transient aura attacks: a transient ischemic attack mimic caused by focal subarachnoid hemorrhage. Stroke 2009;40:3725-3729.
46. Beitzke M, Gattringer T, Enzinger C, Wagner G, Niederkorn K, Fazekas F. Clinical presentation, etiology, and long-term prognosis in patients with nontraumatic convexal subarachnoid hemorrhage. Stroke 2011;42:3055-3060.
47. Charidimou A, Peeters A, Fox Z, Gregoire SM, Vandermeeren Y, Laloux P, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke 2012; 43:2324-2330.
48. Apoil M, Cogez J, Dubuc L, Bataille M, de la Sayette V, Touzé E, et al. Focal cortical subarachnoid hemorrhage revealed by recurrent paresthesias: a clinico-radiological syndrome strongly associated with cerebral amyloid angiopathy. Cerebrovasc Dis 2013;36:139-144.
49. Charidimou A, Baron JC, Werring DJ. Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs. Int J Stroke 2013; 8:105-108.
50. Zhu YC, Chabriat H, Godin O, Dufouil C, Rosand J, Greenberg SM, et al. Distribution of white matter hyperintensity in cerebral hemorrhage and healthy aging. J Neurol 2012;259: 530-536.
51. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, Ni J, Ayres A, Reed A, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. Neurology 2014; 83:794-800.
52. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomog­raphy/magnetic resonance imaging study. Ann Neurol 2013; 73:529-536.
53. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009;72:1230-1235.
54. Gregoire SM, Charidimou A, Gadapa N, Dolan E, Antoun N, Peeters A, et al. Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study. Brain 2011;134:2376-2386.
55. Vallat W, Maundrell A, Leyden J, Kleinig TJ. Cerebral amyloid angiopathy causing cortical microinfarction. J Clin Neurosci 2013;20:1802-1804.
56. Yamada M, Itoh Y, Suematsu N, Otomo E, Matsushita M. Vas­cular variant of Alzheimer’s disease characterized by severe plaque-like beta protein angiopathy. Dement Geriatr Cogn Dis­ord 1997;8:163-168.
57. Cordonnier C, Leys D, Dumont F, Deramecourt V, Bordet R, Pasquier F, et al. What are the causes of pre-existing dementia in patients with intracerebral haemorrhages? Brain 2010;133: 3281-3289.
58. Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011;69:320-327.
59. Yamada M, Itoh Y, Shintaku M, Kawamura J, Jensson O, Thorsteinsson L, et al. Immune reactions associated with cere­bral amyloid angiopathy. Stroke 1996;27:1155-1162.
60. Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MS. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 2004;62:494-497.
61. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55:250-256.
62. Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, et al. Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005;128:500-515.
63. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related in­flammation. Neurology 2007;68:1411-1416.
64. DiFrancesco JC, Brioschi M, Brighina L, Ruffmann C, Sarac­chi E, Costantino G, et al. Anti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: a case report. Neurology 2011;76:842-844.
65. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiap­parini L, Raicher I, et al. Anti-amyloid β autoantibodies in ce­rebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013;73:449-458.
66. Nandigam RN, Viswanathan A, Delgado P, Skehan ME, Smith EE, Rosand J, et al. MR imaging detection of cerebral micro­bleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 2009; 30:338-343.
67. Ii Y, Maeda M, Kida H, Matsuo K, Shindo A, Taniguchi A, et al. In vivo detection of cortical microinfarcts on ultrahigh-field MRI. J Neuroimaging 2013;23:28-32.
68. Radmanesh F, Falcone GJ, Anderson CD, Battey TW, Ayres AM, Vashkevich A, et al. Risk factors for computed tomogra­phy angiography spot sign in deep and lobar intracerebral hemorrhage are shared. Stroke 2014;45:1833-1835.
69. Charidimou A, Meegahage R, Fox Z, Peeters A, Vandermeeren Y, Laloux P, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a mul­ticentre MRI cohort study. J Neurol Neurosurg Psychiatry 2013; 84:624-629.
70. Charidimou A, Jaunmuktane Z, Baron JC, Burnell M, Varlet P, Peeters A, et al. White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology 2014;82:57-62.
71. Charidimou A, Jäger RH, Peeters A, Vandermeeren Y, Laloux P, Baron JC, et al. White matter perivascular spaces are related to cortical superficial siderosis in cerebral amyloid angiopathy. Stroke 2014;45:2930-2935.
72. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J, et al. Impaired visual evoked flow velocity response in cere­bral amyloid angiopathy. Neurology 2008;71:1424-1430.
73. Dumas A, Dierksen GA, Gurol ME, Halpin A, Martinez-Ramirez S, Schwab K, et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol 2012;72:76-81.
74. Peca S, McCreary CR, Donaldson E, Kumarpillai G, Shobha N, Sanchez K, et al. Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 2013; 81:1659-1665.
75. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234.
76. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augusti­nack JC, Johnson KA, et al. Molecular imaging with Pitts­burgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434.
77. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O’Keefe G, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010;74: 487-493.
78. Baron JC, Farid K, Dolan E, Turc G, Marrapu ST, O’Brien E, et al. Diagnostic utility of amyloid PET in cerebral amyloid angi­opathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab 2014;34:753-758.
79. Rutgers KS, van Remoortere A, van Buchem MA, Verrips CT, Greenberg SM, Bacskai BJ, et al. Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol Aging 2011;32:1774-1783.
80. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy. Ann Neurol 2009; 66:245-249.
81. Renard D, Castelnovo G, Wacongne A, Le Floch A, Thou­venot E, Mas J, et al. Interest of CSF biomarker analysis in pos­sible cerebral amyloid angiopathy cases defined by the modi­fied Boston criteria. J Neurol 2012;259:2429-2433.
82. Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, et al. Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis 2012;10:320-323.
83. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical di­agnosis of cerebral amyloid angiopathy: validation of the Bos­ton criteria. Neurology 2001;56:537-539.
84. Greene GM, Godersky JC, Biller J, Hart MN, Adams HP Jr. Surgical experience with cerebral amyloid angiopathy. Stroke 1990;21:1545-1549.
85. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hy­man BT. Apolipoprotein E ε4 and cerebral hemorrhage asso­ciated with amyloid angiopathy. Ann Neurol 1995;38:254-259.
86. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-ε4 alleles in cerebral amyloid angiopa­thy and cerebrovascular pathology associated with Alzheim­er’s disease. Am J Pathol 1996;148:2083-2095.
87. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotein E ε2 allele in hem­orrhage due to cerebral amyloid angiopathy. Ann Neurol 1997; 41:716-721.
88. Brouwers HB, Biffi A, McNamara KA, Ayres AM, Valant V, Schwab K, et al. Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage. Stroke 2012;43:2120-2125.
89. O’Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, et al. Apolipoprotein E genotype and the risk of re­current lobar intracerebral hemorrhage. N Engl J Med 2000; 342:240-245.
90. Maxwell SS, Jackson CA, Paternoster L, Cordonnier C, Thijs V, Al-Shahi Salman R, et al. Genetic associations with brain microbleeds: systematic review and meta-analyses. Neurology 2011;77:158-167.
91. Leclercq PD, Murray LS, Smith C, Graham DI, Nicoll JA, Gen­tleman SM. Cerebral amyloid angiopathy in traumatic brain in­jury: association with apolipoprotein E genotype. J Neurol Neu­rosurg Psychiatry 2005;76:229-233.
92. Hamaguchi T, Okino S, Sodeyama N, Itoh Y, Takahashi A, Otomo E, et al. Association of a polymorphism of the trans­forming growth factor-β1 gene with cerebral amyloid angiop­athy. J Neurol Neurosurg Psychiatry 2005;76:696-699.
93. Peila R, Yucesoy B, White LR, Johnson V, Kashon ML, Wu K, et al. A TGF-β1 polymorphism association with dementia and neuropathologies: the HAAS. Neurobiol Aging 2007;28: 1367-1373.
94. Yamada M. Cerebral amyloid angiopathy and gene polymor­phisms. J Neurol Sci 2004;226:41-44.
95. Yamada M, Sodeyama N, Itoh Y, Suematsu N, Otomo E, Mat­sushita M, et al. Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly. Stroke 1997; 28:2219-2221.
96. Yamada M, Sodeyama N, Itoh Y, Suematsu N, Otomo E, Mat­sushita M, et al. Association of α1-antichymotrypsin polymor­phism with cerebral amyloid angiopathy. Ann Neurol 1998; 44:129-131.
97. Yamada M, Sodeyama N, Itoh Y, Takahashi A, Otomo E, Mat­sushita M, et al. Association of neprilysin polymorphism with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2003;74:749-751.
98. Christoforidis M, Schober R, Krohn K. Genetic-morphologic association study: association between the low density lipo­protein-receptor related protein (LRP) and cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2005;31:11-19.
99. Domingues-Montanari S, Hernandez-Guillamon M, Fernan­dez-Cadenas I, Mendioroz M, Boada M, Munuera J, et al. ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiol Aging 2011;32:551.
100. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE ε4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol 2010;120:169-183.
101. Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K, et al. Genetic variation at CR1 increases risk of ce­rebral amyloid angiopathy. Neurology 2012;78:334-341.
102. Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon S, et al. Effects of perindopril-based lower­ing of blood pressure on intracerebral hemorrhage related toamyloid angiopathy: the PROGRESS trial. Stroke 2010;41: 394-396.
103. Rosand J, Hylek EM, O’Donnell HC, Greenberg SM. Warfa­rin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000;55:947-951.
104. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neu­rol 2004;3:484-492
105. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral micro­bleeds and the risk of intracerebral haemorrhage after throm­bolysis for acute ischaemic stroke: systematic review and me­ta-analysis. J Neurol Neurosurg Psychiatry 2013;84:277-280.
106. Charidimou A, Shakeshaft C, Werring DJ. Cerebral micro­bleeds on magnetic resonance imaging and anticoagulant-as­sociated intracerebral hemorrhage risk. Front Neurol 2012;3: 133.
107. Falcone GJ, Radmanesh F, Brouwers HB, Battey TW, Devan WJ, Valant V, et al. APOE ε variants increase risk of warfarin-related intracerebral hemorrhage. Neurology 2014;83:1139-1146.
108. Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 2009;66:714-720.
109. Thoonsen H, Richard E, Bentham P, Gray R, van Geloven N, De Haan RJ, et al. Aspirin in Alzheimer’s disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke 2010;41:2690-2692.
110. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Aβ immunization on the vascula­ture of human Alzheimer’s disease brain. Brain 2008;131:3299-3310.
111. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61:46-54.
112. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease af­ter immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
113. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retro­spective analysis. Lancet Neurol 2012;11:241-249.
114. Carlson C, Estergard W, Oh J, Suhy J, Jack CR, Siemers E, et al. Prevalence of asymptomatic vasogenic edema in pretreat­ment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 2011;7: 396-401.
115. La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, et al. Structural basis of C-terminal β-amyloid pep­tide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. J Mol Biol 2012;421:525-536.
116. Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronen­berger C, et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese sub­jects with mild-to-moderate Alzheimer’s disease: a multi­center, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther 2013;51:911-923.
117. Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol 2013;36:8-13.
118. Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Bill­ing CB, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Al­zheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 2013;36:14-23.
119. ClinicalTrials.gov. https://clinicaltrials.gov. Accessed on No­vember 7, 2014.
120. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostag­no A, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuro­pathol 2009;118:115-130.
121. Hernandez-Guillamon M, Martinez-Saez E, Delgado P, Domingues-Montanari S, Boada C, Penalba A, et al. MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol 2012; 22:133-141.
122. Lee JM, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci 2005;229-230:249-254.
123. McCarron MO, Nicoll JA, Stewart J, Ironside JW, Mann DM, Love S, et al. The apolipoprotein E ε2 allele and the pathologi­cal features in cerebral amyloid angiopathy-related hemor­rhage. J Neuropathol Exp Neurol 1999;58:711-718.
124. Biffi A, Anderson CD, Jagiella JM, Schmidt H, Kissela B, Han­sen BM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic associ­ation study. Lancet Neurol 2011;10:702-709.